Xilio Therapeutics (XLO) Assets Average (2021 - 2026)
Xilio Therapeutics (XLO) posted Assets Average of $159.1 million for Q1 2026, up 10.33% sequentially from $144.2 million in Q4 2025, and up 82.03% YoY from $87.4 million in Q1 2025.
Xilio Therapeutics (XLO) Assets Average (2021 - 2026) Analysis & Trends
Xilio Therapeutics has reported Assets Average for 6 years, with the latest figure at $159.1 million in Q1 2026.
- Quarterly Assets Average rose 82.03% year-over-year to $159.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $159.1 million (up 82.03% YoY) and the FY2025 annual result came in at $112.9 million, up 71.03% from the prior year.
- Assets Average advanced to $159.1 million in Q1 2026 per XLO's latest filing, from $144.2 million in the prior quarter.
- Over five years, Assets Average peaked at $207.2 million in Q1 2022 and troughed at $69.4 million in Q4 2023.
- A 5-year average of $120.5 million and a median of $118.8 million in 2025 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2025: Assets Average tumbled 53.21% in 2023, then surged 97.88% in 2025.
- Over 5 years, Assets Average stood at $148.3 million in 2022, then sank by 53.21% to $69.4 million in 2023, then increased by 5.02% to $72.9 million in 2024, then soared by 97.88% to $144.2 million in 2025, then gained by 10.33% to $159.1 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $159.1 million, $144.2 million, and $133.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Xilio Therapeutics | 177.75 Mn | 41.71 Mn | - | 158.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 158.87 Mn |
| Mar 31, 2026 | 159.09 Mn |
| Dec 31, 2025 | 144.19 Mn |
| Sep 30, 2025 | 133.75 Mn |
| Jun 30, 2025 | 118.76 Mn |
| Mar 31, 2025 | 87.40 Mn |
| Dec 31, 2024 | 72.87 Mn |
| Sep 30, 2024 | 82.27 Mn |
| Jun 30, 2024 | 86.24 Mn |
| Mar 31, 2024 | 71.77 Mn |
| Dec 31, 2023 | 69.38 Mn |
| Sep 30, 2023 | 85.10 Mn |
| Jun 30, 2023 | 101.93 Mn |
| Mar 31, 2023 | 125.34 Mn |
| Dec 31, 2022 | 148.29 Mn |
| Sep 30, 2022 | 167.77 Mn |
| Jun 30, 2022 | 187.24 Mn |
| Mar 31, 2022 | 207.21 Mn |
| Dec 31, 2021 | 169.39 Mn |